glucose.jpgIPNews® – The Federal Circuit on Friday gave Abbott Diabetes Care Inc. another shot at proving that its two patents for a diabetes-related glucose monitoring system were not invalid in light of prior art, as the U.S. Patent and Trademark Office had found upon reexamination.

The PTO’s Board of Patent Appeals and Interferences adopted unreasonable